New Non-Prescription, Breakthrough Cold Sore Medicine to Hit U.S. Shelves This Summer

Wednesday, July 8th, 2015

Cherry Hill, NJ (PRWEB) May 26, 2015

The brand new, over-the-counter product was developed in Switzerland and will be available in American retail stores for the first time ever this summer. The topical cold sore treatment forms a protective layer over the cold sore, stopping the spread of the virus. Zzip immediately relieves pain and halts itching.

ZZIP USA is proud to announce that ZZIP® Cold Sore medication will be available to the American consumer for the first time this summer. Zzip’s unique, proprietary and patented blend of natural and synthetic ingredients will extend to the U.S. what Europeans began discovering back in 2014. Zzip was developed and engineered in Switzerland by ZZIP AG amongst the natural beauty of the Swiss Alps. That particular region has a long and noted history for products designed with a keen attention to detail and superior ingredients. The Zzip proprietary and patented formula combines active ingredients Dimethicone, Menthol and Allantoin; along with inactive Alpine Rose extract, among other ingredients.

One cold sore sufferer says: “I have hit the lottery in finding Zzip.” Others say Zzip is unlike anything else they have tried: “Zzip quickly relieved the pain, halted itching and the result was indisputable.” Testimonials include people who have suffered 50 or more years of treating recurring cold sores. They say the product had truly unique attributes in immediate and sustained pain relief. You can hear Tom’s story here.

“In 25 years of creating and marketing a wide variety of supplements, cosmetics and other treatments that address ailments of the human condition,” says OTC Pharma CEO, Mario Oldani, “I have never been associated with a product that I believed has so much organic competitive advantages over the other offerings it competes against.”

Introducing the product in the two countries he calls home, Mario’s assessment proved true as the product quickly shot to the #2 bestselling item in the cold sore treatment/ lip care segment in both Switzerland and the Netherlands. After seeing the success of Zzip in Switzerland and the Netherlands, Boot’s, the U.K.’s largest Drug Store Chain, began carrying Zzip in February. Boot’s is owned by Illinois-based Walgreen’s.

“I remember where I was when I heard the news,” stated Martin Uniacke, VP of Sales of ZZIP USA, the American company that is the Exclusive importer of Zzip. “We were in Las Vegas at a pharmacy sales event focused on the Cough and Cold Category where we were making 80 presentations to many of the biggest mass, chain drug and grocery retailers and their distributors, when were told. A cut-in entry, that is to say an accelerated move to put a product on the shelves in one of the largest retail operations in their home market in Europe was a great show of acceptance and eagerness to want to carry the product.”

Uniacke looks ahead to future events. “We attended the ECRM show for the Cough and Cold Category in February in Hendersonville, NV near Las Vegas. We were well received by Walgreen’s, CVS, H.E.B., KMart, Smith Drug and SuperValu, as well as several major distributors and a host of regional independent pharmacies from across the country, many of whom we are following up with now,” says Uniacke.

“My decision to invest my time, energy and money into new endeavors are based on whether or not the initiative meets my ‘doing good and doing well’ litmus test. In the case of becoming the exclusive US importer of Zzip, the product surpassed my criteria,” says Garnick, CEO and Founder of GG Advisors, LLC dba ZZIP USA. “Millions of Americans suffer needlessly from cold sore breakouts due to the insidious HSV1 Virus. Most people don’t realize that an innocent kiss from Grandmom might have transmitted this incurable virus during ones childhood. Zzip’s unique blend of ingredients engineered by a skilled team of doctors and scientists in Switzerland, is an OTC Medicine that we know will help the millions of people who’ve given up on the current available remedies. The products available today simply have proven ineffective for a vast amount of cold sore suffers. We know if cold sore sufferers give Zzip a try that they, like so many Europeans already have experienced who have been using this non-prescription breakthrough medicine since late 2014, will finally get the relief from the painful, embarrassing and untimely cold sores that so many have been struggling with for too long.”

Zzip will be available to American consumers through Amazon in August. In addition, mainstream and local pharmacies across the country will soon carry Zzip, including Hi-School Pharmacy in the Pacific Northwest.

Inquires may contact: Robyn Stevens prmedia(at)live(dot)com 856-885-0913

LUTRONIC’s Innovative Aesthetic and Medical Products Featured at the 13th Anti-Aging Medicine World Congress

Wednesday, April 22nd, 2015

Fremont, CA (PRWEB) April 02, 2015

Lutronic, a leading innovator of aesthetic and medical technology, announced today that it expands its portfolio of innovative medical solutions in Europe with ACTION II Petit Lady ™ at the 13th Anti-Aging Medicine World Congress (AMWC) in Monte-Carlo, Monaco, from March 26-28, 2015. ACTION II is a device that provides a new dimension in Er:YAG laser technology applied for both gynecological and aesthetic indications. It received CE mark clearance for treatment of vaginal relaxation syndrome (VRS) and stress urinary incontinence (SUI) in June 2014, which expands its clinical applications and builds on the success of the original ACTION II device which primarily focused on aesthetic treatments.

“I have seen that ACTION II Petit Lady increases the elasticity of the vaginal wall with a significantly short downtime. Patients suffering from vaginal relaxation syndrome are very satisfied with Petit Lady because this 15-minute non-surgical treatment successfully rejuvenates the vagina and enhances sexual gratification,” said Dr Fabio Marini, a surgeon at the Skin Laser Clinic, in Italy. Dr Marini was presenting on the Petit Lady system at a special dinner Symposium during the AMWC, ‘Symposia L’, hosted by Lutronic. Dr Marini also presented his one year clinical study on ACTION II Petit Lady for vaginal atrophy and vaginal relaxation syndrome, which showed significant improvements in both sets of patients.

The well-attended symposium, which was moderated by Dr R Glen Calderhead, VP Medicoscientific Affairs for Lutronic, also featured Dr. Matteo Tretti Clementoni, a plastic surgeon at Skin House in Italy Dr Clementoni, a world-renowned physician, shared his knowledge of the INFINI™ for treating neck and low face laxity with its High Intensity Focused RF. “The device is very easy to use, and it is possible to perform full face and neck treatment in less than 15 minutes. With varying energy, pulse duration, depth of needles penetration and number of passages, it is possible to customize the treatment for the specific skin needs of each patient on an individual basis. Finally, we have a device/treatment that really allows us to obtain good results on the lower 1/3 of the face and the neck,” he added. Another presenter of INFINI, Dr Harryono Judodihardjo, a dermatologist from the Cellite Clinic, UK also shared his clinical experiences with the title, ‘How to Smooth Out Accordion Lines (Smile Lines).’

Another star speaker was Dr Christine Dierickx, a world-wide respected dermatologist from Skinperium, Belgium, who presented on the Q-switched Nd:YAG-based multiplatform, SPECTRA XT™, which is the latest edition of the cutting-edge SPECTRA family of lasers, already best-known and appreciated for its versatility and reliability.

The symposium was a great success, judging from the many favorable comments from the attendees who were most impressed by the practical and solid nature of the presentations and the range of topics covered by the well-appreciated presenters. This symposium built on the success of the similar event at last year’s AMWC, and many of those present stated that they would definitely be looking to attend again next year, hoping that it will become a tradition to be established by Lutronic at subsequent AMWC meetings.

About ACTION II Petit Lady

The Lutronic ACTION Petit Lady is a 360° solution for cosmetic gynecology. The treatment is gentle, simple and fast. The ACTION II Petit Lady 360° handpiece is specially designed for VRS. It delivers multiple micropulses to the vaginal mucosa to stimulate collagen remodeling and tighten the vaginal canal. The ACTION II Petit Lady 90º handpiece is intended for SUI, providing an enhanced thermal and shrinkage effect in the endopelvic fascia, ligaments, and mucosal tissue of the anterior vaginal canal.

To learn more about the ACTION II Petit Lady, please visit:


Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established over 18 years ago to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple setting and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions and treatments including melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, skin resurfacing, body/facial contouring, chronic pain and more.

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 240 intellectual properties including current and pending patents worldwide. With more than 250 employees worldwide, Lutronic has offices in the US, Korea, China, Japan, and Europe, a worldwide network of distributors, and is ever expanding.

For more information about Lutronic and its products, please visit:

Global Stem Cells Group to Participate in the 25th Argentine Congress of Aesthetic Medicine in Buenos Aires April 9-10, 2015

Monday, April 20th, 2015

MIAMI (PRWEB) March 17, 2015 has announced plans to participate in the 25th annual Argentine Congress of Aesthetic Medicine April 9 and 10 2015. More than 1,000 physicians from around the world will descend on Buenos Aires for the conference to learn and share new findings in aesthetic medicine.

Following the congress, Global Stem Cells Group and Estanislao Janowski, M.D., a plastic surgeon specializing in stem cell application in aesthetic and cosmetic medicine will conduct an intensive, hands-on course on stem cell harvesting, isolation and re-integration, to be held April 11. Janowski, a GSCG faculty member and long-time collaborator is the owner and president of Bioplastica, an aesthetic surgical center featuring the latest stem cell applications in cosmetic and anti-aging medicine.

This will be the third year Global Stem Cells Group participates in the conference, hosted by the Argentina Society of Aesthetic Medicine (SOARME). A soon-to-be-named GSCG faculty member will also deliver a keynote speech to congress attendees.

The international event, which will be held at the Catholic University of Argentina in Buenos Aires, will feature acclaimed stem cell aesthetic practitioners from Argentina and the U.S. SOAME is a member of the Argentine Medical Association (A.M.A.) and of the International Union of Aesthetic Medicine (U.I.M.E.). SOAME has the scientific support of the John F. Kennedy University in Buenos Aires and a host of national and international scientific organizations.

For more information visit the Global Stem Cells Group website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.

With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.


Related Organic Cosmetics Press Releases